Syngene International Limited (SYNGENE.BO)
INR 627.85
(-0.83%)
INR 627.85
(-0.83%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 34.88 Billion INR | 13.26% |
| 2022 | 30.8 Billion INR | 22.88% |
| 2021 | 25.06 Billion INR | 19.99% |
| 2020 | 20.89 Billion INR | 11.14% |
| 2019 | 18.79 Billion INR | 9.57% |
| 2018 | 17.15 Billion INR | 29.53% |
| 2017 | 13.24 Billion INR | 13.25% |
| 2016 | 11.69 Billion INR | 7.73% |
| 2015 | 10.85 Billion INR | 28.82% |
| 2014 | 8.42 Billion INR | 22.65% |
| 2013 | 6.87 Billion INR | 27.36% |
| 2012 | 5.39 Billion INR | 32.07% |
| 2011 | 4.08 Billion INR | 29.27% |
| 2010 | 3.16 Billion INR | 19.74% |
| 2009 | 2.63 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 7.89 Billion INR | -13.87% |
| 2024 Q2 | 8.91 Billion INR | 12.83% |
| 2023 Q3 | 8.53 Billion INR | -6.22% |
| 2023 Q1 | 8.08 Billion INR | -8.35% |
| 2023 Q2 | 9.1 Billion INR | 12.62% |
| 2023 FY | 34.88 Billion INR | 13.26% |
| 2023 Q4 | 9.16 Billion INR | 7.43% |
| 2022 Q4 | 8.81 Billion INR | 12.19% |
| 2022 FY | 30.8 Billion INR | 22.88% |
| 2022 Q1 | 6.44 Billion INR | -2.44% |
| 2022 Q2 | 7.68 Billion INR | 19.18% |
| 2022 Q3 | 7.85 Billion INR | 2.32% |
| 2021 Q2 | 6.1 Billion INR | 2.64% |
| 2021 FY | 25.06 Billion INR | 19.99% |
| 2021 Q3 | 6.41 Billion INR | 5.11% |
| 2021 Q1 | 5.94 Billion INR | 5.52% |
| 2021 Q4 | 6.6 Billion INR | 2.99% |
| 2020 Q3 | 5.84 Billion INR | 12.49% |
| 2020 FY | 20.89 Billion INR | 11.14% |
| 2020 Q4 | 5.63 Billion INR | -3.61% |
| 2020 Q2 | 5.19 Billion INR | 23.24% |
| 2020 Q1 | 4.21 Billion INR | -11.26% |
| 2019 FY | 18.79 Billion INR | 9.57% |
| 2019 Q2 | 4.64 Billion INR | 10.2% |
| 2019 Q1 | 4.21 Billion INR | -0.54% |
| 2019 Q4 | 4.75 Billion INR | -8.48% |
| 2019 Q3 | 5.19 Billion INR | 11.73% |
| 2018 Q4 | 4.23 Billion INR | -9.25% |
| 2018 FY | 17.15 Billion INR | 29.53% |
| 2018 Q1 | 4.06 Billion INR | -0.76% |
| 2018 Q2 | 4.18 Billion INR | 3.1% |
| 2018 Q3 | 4.67 Billion INR | 11.59% |
| 2017 FY | 13.24 Billion INR | 13.25% |
| 2017 Q4 | 4.09 Billion INR | 5.52% |
| 2017 Q3 | 3.87 Billion INR | 15.66% |
| 2017 Q2 | 3.35 Billion INR | 15.15% |
| 2017 Q1 | 2.91 Billion INR | -0.07% |
| 2016 Q3 | 3.23 Billion INR | 6.86% |
| 2016 Q2 | 3.03 Billion INR | 10.38% |
| 2016 Q1 | 2.74 Billion INR | -17.19% |
| 2016 FY | 11.69 Billion INR | 7.73% |
| 2016 Q4 | 2.91 Billion INR | -10.04% |
| 2015 Q4 | 3.31 Billion INR | 20.5% |
| 2015 Q2 | 2.56 Billion INR | 12.18% |
| 2015 Q1 | 2.28 Billion INR | -7.53% |
| 2015 Q3 | 2.75 Billion INR | 7.42% |
| 2015 FY | 10.85 Billion INR | 28.82% |
| 2014 FY | 8.42 Billion INR | 22.65% |
| 2014 Q3 | 2.22 Billion INR | 12.57% |
| 2014 Q2 | 1.97 Billion INR | 6.12% |
| 2014 Q1 | 1.86 Billion INR | 0.0% |
| 2014 Q4 | 2.46 Billion INR | 10.82% |
| 2013 FY | 6.87 Billion INR | 27.36% |
| 2012 FY | 5.39 Billion INR | 32.07% |
| 2011 FY | 4.08 Billion INR | 29.27% |
| 2010 FY | 3.16 Billion INR | 19.74% |
| 2009 FY | 2.63 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alfavision Overseas (India) Limited | 31.27 Million INR | -111453.097% |
| Biocon Limited | 147.55 Billion INR | 76.358% |
| Blue Jet Healthcare Limited | 7.11 Billion INR | -390.249% |
| Concord Biotech Limited | 10.16 Billion INR | -243.049% |
| Dishman Carbogen Amcis Limited | 26.15 Billion INR | -33.368% |
| FERMENTA BIOTECH LIMITED | 3.35 Billion INR | -939.32% |
| GENOMIC VALLEY BIOTECH LIMITED | 1.65 Million INR | -2113242.42% |
| Lyka Labs Limited | 1.05 Billion INR | -3218.295% |
| Panacea Biotec Limited | 5.51 Billion INR | -532.074% |
| SAMSRITA LABS LIMITED | - INR | -Infinity% |
| Servoteach Industries Limited | - INR | -Infinity% |
| SMS Lifesciences India Limited | 3.05 Billion INR | -1040.22% |
| Supriya Lifescience Limited | 5.7 Billion INR | -511.638% |
| TAKE Solutions Limited | 656.08 Million INR | -5217.339% |
| Titan Biotech Limited | 1.64 Billion INR | -2026.26% |
| Transgene Biotek Limited | 2.34 Million INR | -1485042.614% |
| Vanta Bioscience Limited | 97.22 Million INR | -35780.241% |